These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 23209008)

  • 21. Potential role of non-insulin adjunct therapy in Type 1 diabetes.
    George P; McCrimmon RJ
    Diabet Med; 2013 Feb; 30(2):179-88. PubMed ID: 22804102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
    Green BD; Flatt PR; Bailey CJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapy of hyperglycemia.
    Kulasa KM; Henry RR
    Expert Opin Pharmacother; 2009 Oct; 10(15):2415-32. PubMed ID: 19743938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
    Russell S
    Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Tahrani AA; Piya MK; Barnett AH
    Adv Ther; 2009 Mar; 26(3):249-62. PubMed ID: 19330494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
    Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
    Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of incretin-based therapies in the management of type 2 diabetes.
    Bandyopadhyay P
    Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
    Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
    Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.
    Tan X; Hu J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1285-93. PubMed ID: 27156529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia].
    Wang JS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):229-33. PubMed ID: 23643015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N
    Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
    Ahrén B
    J Diabetes Investig; 2021 Jul; 12(7):1128-1135. PubMed ID: 33949781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond insulin: what else might help?
    Scheiner G
    Diabetes Self Manag; 2014; 31(1):30, 32-4. PubMed ID: 24640060
    [No Abstract]   [Full Text] [Related]  

  • 39. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
    Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
    Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What role will 'gliptins' play in glycemic control?
    Bloomgarden Z; Drexler A
    Cleve Clin J Med; 2008 Apr; 75(4):305-10. PubMed ID: 18491437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.